ARTICLE | Clinical News
Numient carbidopa/levodopa regulatory update
October 5, 2015 7:00 AM UTC
EMA’s CHMP recommended approval of Numient carbidopa/levodopa from Impax for the symptomatic treatment of adults with Parkinson’s disease. Impax markets the product as Rytary in the U.S. (see BioCentu...